Market Cap 375.09B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.98
Forward PE 14.95
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 3,814,054
Avg Vol 6,780,002
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 91%
Beta 0.32
Analysts Strong Sell
Price Target $251.14

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
mebotta10
mebotta10 May. 22 at 2:31 PM
$HCWB breakthroughs with huge potential and a market cap of 17million. Will eat into $ABBV revenue with their autoimmune treatment.
0 · Reply
StockElementCorporation
StockElementCorporation May. 22 at 2:10 PM
Ripping . Did you catch it ? $OSS , $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:46 PM
$SLS GPS BLA for CR1 - I put this together for those who may not have the FULL Understanding. • GPS PH 2 CR1 TRIAL MOS Not Yet Reached > 67.6 months ... is better than transplant. The Share Price will continue climbing until the 80th Event PR and then it will Launch - and then We will see ballistic VERTICALITY on the P3 Top Line Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes. in Count Down Mode. - Event rates are not linear, with follow-up ranging from 25 to 62 months. --- 80th Event may have already occurred, waiting to cycle through the data collection process.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:41 PM
$SLS $LLY $ABBV From the Presentation - xCCO Estimating Minimum Revenue Per Patient for GPS in Year 1. Subsequently - REGAL Clinicians Requested - Continued Dosing Beyond Year 1 Year 2 6 X Per Year Booster Series / $110K Year 3 4 X Per Year Booster Series / $70K
0 · Reply
Loudermilk64
Loudermilk64 May. 22 at 1:39 PM
$ABBV AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C infection (HCV) in adults and children aged 3 years and older. The final European Commission decision is expected in the third quarter of 2026. If approved, MAVIRET would be indicated for both acute and chronic hepatitis C (HCV) infection in the European Union.
0 · Reply
StockElementCorporation
StockElementCorporation May. 22 at 1:36 PM
Trade Plan 5/22 ☀️ $OSS break over 17.04, 20c Jul $ABBV break over 214.5, 220c Jun 18 $MRAM break over 33, looking for shares $AFRM break over 69, 75c Jun 18
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:14 PM
$SLS $LLY $ABBV Gps Immunotherapy is getting the Fda Approval to Treat 100,000 AML patients currently in Remission. The xCCo Estimated $280K Revenue Per Patient Year 1. Indefinite Multi Year Dosing Regime Compounds the Rev. - $28B Total Addressable Market - Right out of the GATE Plus 12,500 AML CR2/3 Patients who are Eligible Each Year ... Just this CR2/3 Market is worth $75 Per Share. TAM - rNPV - Just for CR2/3 - Cr1 is worth 3-4x
0 · Reply
focafoca99
focafoca99 May. 22 at 12:19 PM
$ABBV won a positive CHMP opinion for MAVIRET to treat acute hepatitis C. https://www.rapidticker.com/news/abbv-abbvie-announces-positive-chmp-opinion-8da792
0 · Reply
focafoca99
focafoca99 May. 21 at 10:55 PM
$ABBV disclosed new ASCO 2026 oncology data spanning solid tumors and blood cancers. https://www.rapidticker.com/news/abbv-abbvie-announces-new-data-at-4271c6
0 · Reply
Fosco_
Fosco_ May. 21 at 9:12 PM
$IMMX Some ASCO data is out. This morning layout perfectly anticipated tonight's ASCO abstracts. Regeneron’s Linvoseltamab ($REGN LINKER-AL2) shows solid response but highlights persistent continuous-dosing toxicity risks. AbbVie’s Ententamig ($ABBV) faces standard bispecific multi-dose fatigue. AstraZeneca/Gracell's dual CAR-T (AZD0120) requires heavy logistics/hospitalization constraints. Meanwhile, Immix’s NXC steals the show. An unparalleled 95% Complete Response rate with zero relapses locks in NXC-201 as a true one-and-done outpatient functional cure
1 · Reply
Latest News on ABBV
AbbVie reports positive CHMP opinion for Maviret

2026-05-22T12:12:15.000Z - 2 hours ago

AbbVie reports positive CHMP opinion for Maviret

ABBV


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 14 days ago

AbbVie Transcript: AGM 2026


AbbVie price target raised to $265 from $262 at Canaccord

2026-04-30T13:31:03.000Z - 22 days ago

AbbVie price target raised to $265 from $262 at Canaccord

ABBV


AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:15:57.000Z - 22 days ago

AbbVie upgraded to Buy at BofA on durable growth

ABBV


AbbVie upgraded to Buy from Neutral at BofA

2026-04-30T10:14:18.000Z - 22 days ago

AbbVie upgraded to Buy from Neutral at BofA

ABBV


AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:58.000Z - 22 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

ABBV


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 23 days ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 23 days ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 23 days ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 23 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

ABBV


AbbVie reports Q1 adjusted EPS $2.65, consensus $2.67

2026-04-29T12:15:43.000Z - 23 days ago

AbbVie reports Q1 adjusted EPS $2.65, consensus $2.67

ABBV


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 23 days ago

AbbVie Reports First-Quarter 2026 Financial Results

ABBV


US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 4 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment

ABBV


AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

ABBV


AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing


AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing


Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

ABBV


AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026


AbbVie Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing


AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference


mebotta10
mebotta10 May. 22 at 2:31 PM
$HCWB breakthroughs with huge potential and a market cap of 17million. Will eat into $ABBV revenue with their autoimmune treatment.
0 · Reply
StockElementCorporation
StockElementCorporation May. 22 at 2:10 PM
Ripping . Did you catch it ? $OSS , $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:46 PM
$SLS GPS BLA for CR1 - I put this together for those who may not have the FULL Understanding. • GPS PH 2 CR1 TRIAL MOS Not Yet Reached > 67.6 months ... is better than transplant. The Share Price will continue climbing until the 80th Event PR and then it will Launch - and then We will see ballistic VERTICALITY on the P3 Top Line Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes. in Count Down Mode. - Event rates are not linear, with follow-up ranging from 25 to 62 months. --- 80th Event may have already occurred, waiting to cycle through the data collection process.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:41 PM
$SLS $LLY $ABBV From the Presentation - xCCO Estimating Minimum Revenue Per Patient for GPS in Year 1. Subsequently - REGAL Clinicians Requested - Continued Dosing Beyond Year 1 Year 2 6 X Per Year Booster Series / $110K Year 3 4 X Per Year Booster Series / $70K
0 · Reply
Loudermilk64
Loudermilk64 May. 22 at 1:39 PM
$ABBV AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C infection (HCV) in adults and children aged 3 years and older. The final European Commission decision is expected in the third quarter of 2026. If approved, MAVIRET would be indicated for both acute and chronic hepatitis C (HCV) infection in the European Union.
0 · Reply
StockElementCorporation
StockElementCorporation May. 22 at 1:36 PM
Trade Plan 5/22 ☀️ $OSS break over 17.04, 20c Jul $ABBV break over 214.5, 220c Jun 18 $MRAM break over 33, looking for shares $AFRM break over 69, 75c Jun 18
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 1:14 PM
$SLS $LLY $ABBV Gps Immunotherapy is getting the Fda Approval to Treat 100,000 AML patients currently in Remission. The xCCo Estimated $280K Revenue Per Patient Year 1. Indefinite Multi Year Dosing Regime Compounds the Rev. - $28B Total Addressable Market - Right out of the GATE Plus 12,500 AML CR2/3 Patients who are Eligible Each Year ... Just this CR2/3 Market is worth $75 Per Share. TAM - rNPV - Just for CR2/3 - Cr1 is worth 3-4x
0 · Reply
focafoca99
focafoca99 May. 22 at 12:19 PM
$ABBV won a positive CHMP opinion for MAVIRET to treat acute hepatitis C. https://www.rapidticker.com/news/abbv-abbvie-announces-positive-chmp-opinion-8da792
0 · Reply
focafoca99
focafoca99 May. 21 at 10:55 PM
$ABBV disclosed new ASCO 2026 oncology data spanning solid tumors and blood cancers. https://www.rapidticker.com/news/abbv-abbvie-announces-new-data-at-4271c6
0 · Reply
Fosco_
Fosco_ May. 21 at 9:12 PM
$IMMX Some ASCO data is out. This morning layout perfectly anticipated tonight's ASCO abstracts. Regeneron’s Linvoseltamab ($REGN LINKER-AL2) shows solid response but highlights persistent continuous-dosing toxicity risks. AbbVie’s Ententamig ($ABBV) faces standard bispecific multi-dose fatigue. AstraZeneca/Gracell's dual CAR-T (AZD0120) requires heavy logistics/hospitalization constraints. Meanwhile, Immix’s NXC steals the show. An unparalleled 95% Complete Response rate with zero relapses locks in NXC-201 as a true one-and-done outpatient functional cure
1 · Reply
focafoca99
focafoca99 May. 21 at 8:53 PM
$ABBV rallies on positive CHMP opinion for Boey in Europe. https://www.rapidticker.com/news/abbv-allergan-aesthetics-receives-positive-chmp-23cd11
0 · Reply
Blockwave1
Blockwave1 May. 21 at 8:35 PM
Just THIS WEEK I gave YOU ALL over 2,799% in GAINS for COMPLETELY FREE..(STOCKSWITS)🔥 I GAVE YOU $IBM 22 MAY 26 $240 CALL FOR 1,171% 🥰 I GAVE YOU $HD 22 MAY 26 $415 CALL FOR 400% 🥰 I GAVE YOU $IBM 29 MAY 26 $245 CALL FOR 400% 🥰 I GAVE YOU $AAPL 22 MAY 26 $300 CALL FOR 263% 🥰 I GAVE YOU $COST 22 MAY 26 $1,120 CALL FOR 203% 🥰 I GAVE YOU $COST 22 MAY 26 $1,110 CALL FOR 201% 🥰 I GAVE YOU $ABBV 22 MAY 26 $222.5 CALL FOR 156% 🥰 Turn on post notifications on STOCKWITS🔥 Feel free to join the telegram channel🤙
1 · Reply
Blockwave1
Blockwave1 May. 21 at 8:21 PM
$ABBV 🔥 $222.5 22 MAY 26 (W) CALL 100 $0.23 ➡️ $0.59 🔥 156% GAINER! 🔥 To the moon🤙🚀
0 · Reply
luckyfreedom
luckyfreedom May. 21 at 6:58 PM
$COSM I am still here - just waiting for next the base. I got stopped out on my initial entry. By the way - This is not my priority investment, my time is valuable. Someone couldn’t pay me enough to post here all day long like you Jim. Other stocks I took positions on this morning: $MP $ABBV $HOOD $ANET
1 · Reply
nlrmandate
nlrmandate May. 21 at 6:27 PM
$VKTX I've always favored $ABBV over $NVO as a buyer of Viking. However, with today's Retatrutide trial results, I actually think a BO by NVO has become MORE likely for Viking. With NVO's recent performance, it seems fairly clear that the market views NVO as yesterday's news. It can't buy Reta because LLY won't sell and because Reta isn't very tolerable as a general weight loss drug anyway (as opposed to perhaps a niche player for morbid obesity/bodybuilding). BUT, what it can do is buy the company with THE ONLY REMAINING clinical weight loss asset with the chops to challenge BOTH Terz and Reta....and that would be Viking. I still personally hope it's ABBV that buys Viking, but they need to make a move before NVO wises up and beats them to the punch! And don't think NVO can't afford Viking; from where I sit, they can't afford NOT to BO Viking! Long and insanely
5 · Reply
mebotta10
mebotta10 May. 21 at 5:34 PM
$HCWB $ABBV is cooked!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 8:13 PM
$SLS Always nice to see a new 52 week / 5 year HIGH while waiting for Phase 3 Trial Results. $ABBV $BMY $RHHBY Know GPs is preventing relapse and Extending survival, doing what its done in ALL Previous Trials and is the only reason we are waiting for Near Miraculous Survival Data - they Own the BAT / Aza +VEN - Aza VEN Recently FAILED 3 Large Phase 3 trials conducted by $ABBV - Including 2 for AML Remission Maintenance.
0 · Reply
BillionerOfKing
BillionerOfKing May. 20 at 5:40 PM
$ABBV Current Stock Price: $212.99 Contracts to trade: $212.5 ABBV May 22 2026 Call Entry: $1.99 Exit: $3.56 ROI: 79% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 5:21 PM
$SLS Must really Gobble SCHLONG being short here now, knowing the 80th EVENT IS COMING and and their Short Lies are worn thin. - 80th EVEN PR WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....
1 · Reply
OnTheBalance
OnTheBalance May. 20 at 5:00 PM
$SLS $LLY $ABBV The 80th Event is NOW Around the Corner.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 4:51 PM
$SLS The Share Price will continue climbing until the 80th Event PR and then it will Launch - and then We will see ballistic VERTICALITY on the P3 Top Line Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes. in Count Down Mode. - Event rates are not linear, with follow-up ranging from 25 to 62 months. --- 80th Event may have already occurred, waiting to cycle through the data collection process.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 20 at 3:59 PM
$SLS Must really Suck A** being short here now, knowing the 80th EVENT IS COMING and WILL LAUNCH THE SHARE PRICE. ps Does Everyone Know BAT/ Best Available Treatment for Control Arm Patients - Aza+VEN Recently Failed 3 Large Phase 3 Trials conducted by $ABBV ? Including Failing 2 For AML Remission Maintenance... this is a $90 Stock trading for $9....
0 · Reply